OTCMKTS:ZLDPF Zealand Pharma A/S Q1 2025 Earnings Report $46.38 0.00 (0.00%) As of 09/10/2026 ProfileEarnings HistoryForecast Zealand Pharma A/S EPS ResultsActual EPS-$0.67Consensus EPS -$0.77Beat/MissBeat by +$0.10One Year Ago EPSN/AZealand Pharma A/S Revenue ResultsActual Revenue$1.14 millionExpected Revenue$248.61 millionBeat/MissMissed by -$247.47 millionYoY Revenue GrowthN/AZealand Pharma A/S Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsZealand Pharma A/S' next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Zealand Pharma A/S Earnings HeadlinesZealand Pharma A/S (OTCMKTS:ZLDPF) Cut to Hold at BarclaysSeptember 11 at 1:30 AM | americanbankingnews.comZealand Pharma: A Play On Medicine Discovery, But Too Expensive Right NowSeptember 9 at 9:56 AM | seekingalpha.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.September 11 at 1:00 AM | Profits Run (Ad)Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)August 24, 2026 | markets.businessinsider.comZealand Pharma â Notification of holding of treasury sharesAugust 24, 2026 | markets.businessinsider.comZealand Pharma A/SAugust 20, 2026 | barrons.comSee More Zealand Pharma A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zealand Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zealand Pharma A/S and other key companies, straight to your email. Email Address About Zealand Pharma A/SZealand Pharma A/S (OTCMKTS:ZLDPF) is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. The company’s research programs address serious and underserved conditions, particularly metabolic diseases, gastrointestinal disorders and rare diseases. Zealand combines proprietary peptide technologies with drug-development expertise to create therapies designed to improve treatment outcomes and patient convenience. Zealand’s commercial portfolio includes Zegalogue (dasiglucagon), an injectable treatment for severe hypoglycemia in people with diabetes. The company is also advancing a pipeline of investigational medicines, including treatments for obesity, metabolic dysfunction and other chronic conditions. Several programs are being developed through collaborations with international pharmaceutical companies, including a partnership with Boehringer Ingelheim for survodutide, an investigational medicine being studied in metabolic disease. Founded in 1998, Zealand Pharma is headquartered in Søborg, Denmark, and serves international markets through its own commercial activities and strategic partnerships. The company’s leadership is headed by Chief Executive Officer Adam Steensberg, who has overseen the organization’s focus on late-stage development, commercialization and partnerships in metabolic and rare-disease medicine.View Zealand Pharma A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsAmgen Drops 10% on a Trial It Didn't Even RunAST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing WindowAeroVironment's Record Backlog and Earnings Beat Fuel Recovery CaseBlock Makes a Federal Trust Bank Move That Could Reshape Its Fintech ModelCould Snowflake's Big Quarter Be a Sign of More to Come? Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
